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1146-114 Coronary Artery Disease in Patients With Multiple 
Emergency Department Visits and Negative Immediate 
Exercise Tests for Chest Pain: An Important Minority in 
a Total Cohort of Over 3,000 Low-Risk Patients 
Presenting With Chest Pain
Ezra A. Amsterdam, J. Douglas Kirk, Deborah Diercks, Larry Baker, Erin Madriago, 
Danny Yen, University of California, Davis, Sacramento, CA
Background: Low risk patients (pts) presenting to our emergency department (ED) with
chest pain undergo immediate exercise testing (IET).
Methods: IET was performed in all low risk pts presenting to the ED with chest pain and
results and clinical outcome were analyzed with particular reference to the group with
multiple visits and negative IETs.
Results: Of 3,432 patients tested during a 7.5 year interval, IET was positive in 353
(10.3%), nondiagnostic in 830 (24.2%) and negative in 2,249 (65.5%). During the study
period, 289 (13%) of the 2249 pts with negative tests had multiple (>2) IET for chest pain.
The total number of negative IET during the study period was 2,656 which were obtained
in 1,960 pts with single IET and in the multivisit (MV) subgroup of 289 pts who had 696
negative IET. Thus, the MV subgroup comprised 13% (289/2,249) of all pts with negative
IET but accounted for 26% (696/2656) of the total number of negative IET. In the MV sub-
group (n=289), 261 (90.3%) pts had 2-3 IET and 28 (8.7%) had >4 IET. The mean num-
ber of IET in the MV subgroup = 2.7 (range 2-7). The MV negative subgroup was similar
(p>0.05) in age (52 vs. 51 yr) and number of cardiac risk factors (1.5 vs. 1.5) to the single
negative IET pts but the proportion of women was higher in MV (54% vs. 44%, p<0.05).
In the MV negative IET pts, there was no cardiac mortality, 7 (2.4%) pts ultimately had
myocardial infarction and after a mean of 3.7 tests, 25 underwent cardiac catheterization
showing critical coronary artery disease and 24 (8.3%) of these pts had myocardial
revascularization.
Conclusions: Although a minority of negative IET pts had multiple visits to the ED, they
accounted for a disproportionate number of the IET by the entire negative group. An
important minority of the MV negative subgroup was ultimately found to have coronary
artery disease after multiple tests and were candidates for revascularization. Earlier
definitive evaluation of MV pts could obviate repeat visits in many and afford appropriate
therapy for coronary artery disease in an important minority.
ORAL CONTRIBUTIONS
849 Heart Failure, Basic Science, Animal 
Models, and Human Studies
Tuesday, March 09, 2004, 2:00 p.m.-3:30 p.m.
Morial Convention Center, Room 217
2:00 p.m.
849-1 Uncoupling Proteins Shift During Cardiac Hypertrophy 
and Renin-Angiotensin System Suppression
Susan Marie Dallabrida, Maria Ann Rupnick, Brigham and Women's Hospital, Boston, 
MA, Children's Hospital, Boston, MA
Background: Improving energetics during heart failure may aid to preserve cardiac func-
tion. Uncoupling proteins (UCP) are key regulators of energetics in skeletal muscle and
adipose tissue. They reduce the proton electrochemical gradient across the innermito-
chondrial membrane. However, their role in cardiac tissue is poorly understood. In mice
with heart failure, increased UCP2 coincides with reduced high-energy phosphates. In
humans, reduced UCP3 in failing hearts is normalized with left ventricular assist devices.
RAAS suppression with angiotensin converting enzyme (ACE) inhibitors or angiotensin
receptor I (ATR1) blockers improve cardiac function and reduce remodeling. We asked if
these benefits were associated with improved cardiac energetics.
Methods: We examined UCP1, UCP2, UCP3 mRNA levels (real-time RT-PCR) in thy-
roid-hormone (T3)-induced cardiac hypertrophy (C57BL/6 mice) and in mice given T3
plus an antiangiogenic drug, TNP-470 on 1-4, 14 d. We measured the effect of captopril
or candesartan (14 d) on UCPs in C57BL/6 mice. Body, left/right ventricles, and atria
weights and tibia length were assessed.
Results: T3-induced hypertrophy increased left ventricle (LV) UCP2 and UCP3 mRNA
levels, and reduced UCP1. Compared to controls, UCP2 increased 5 fold (1, 2 d), 10 fold
(3 d), and 20 fold (4 d) with no further increases despite continued LV increases (14 d).
The UCP2 increases coincided with the most angiogenic phase (1-4 d) of T3-induced
hypertrophy. We examined the effects of an antiangiogenic agent, TNP-470, on UCP
shifts and hypertrophy. We treated mice with T3 plus TNP-470 (1, 4 d). TNP-470 reduced
UCP2 to normal and limited increases in LV mass (T3: 117+12 mg; T3+TNP-470: 94+6.0
mg), but did not negate UCP3 or UCP1 shifts. In addition, mice given captopril or cande-
sartan (14 d) had reduced UCP2 levels (2 fold) and LV weights (controls: 125+10; capto-
pril: 94+4; candesartan: 95+2 mg). UCP3 and UCP1 were unchanged.
Conclusion: UCPs may be important regulators of cardiac energetics. Perturbations
may contribute to heart failure. Agents that normalize UCP expressions (ie: TNP-470,
ACE inhibitors/ATR1 blockers) may improve cardiac function during hypertrophy and fail-
ure.
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849-2 Left Ventricular Assist Device Support Fails to 
Normalize the Beta-1/Beta-2 Adrenergic Receptor Ratio 
in Human Heart Failure
Wendy E. Sweet, Maria Yared, Monique L. Ogletree, Patrick M. McCarthy, James B. 
Young, Christine S. Moravec, Cleveland Clinic Foundation, Cleveland, OH
Background: Human heart failure is associated with a decreased response to beta-adr-
energic stimulation due to a decrease in beta-adrenergic receptors, particularly a
decrease in density of beta-1 receptors.During heart failure, the ratio of beta-1/beta-2
receptors is approximately 60/40, as compared to 80/20 in non-failing hearts. We have
shown that following left ventricular assist device (LVAD) support of the failing heart, total
receptor density recovers quickly, but recovery of the inotropic response to stimulation is
delayed. This study tested the hypothesis that delayed recovery of inotropy is due to a
delayed restoration in the ratio of beta-1/beta-2 adrenergic receptors.
Methods: Inotropic responsiveness to one micromolar isoproterenol was measured in
isolated, isometrically contracting human trabecular muscles from tissue removed at
LVAD implant and explant. Total beta receptor density were quantified in the same tissue
pairs by Scatchard analysis using radiolabeled cyanopindolol, while receptor subtypes
were determined by two-site competition binding curves using 15 doses of ICI 118,551.
Results: At time of LVAD explant, the inotropic response to isoproterenol was greater
(149 ± 29%) as compared to the time of implant (68 ± 14%, p < 0.05), and the response
continued to improve with increased duration of support (p < 0.05). Total receptor density
was increased after LVAD (72.3 ± 7.8 vs 24.2 ± 3.6 fmol/mg protein; p < 0.0001),
whereas the percent of beta-1 receptors was not different between the two groups (64.4
± 6.1% at implant; 68.4 ± 2.0% at explant). While the percent of beta-1 receptors was not
changed, the absolute number of both beta-1 (50.3 ± 6.4 vs 19.4 ± 3.5 fmol/mg protein, p
< 0.001) and beta-2 receptors (21.9 ± 2.2 vs 10.8 ± 2.6 fmol/mg protein, p < 0.05) was
increased after LVAD.
Conclusion: Although the total density of beta-adrenergic receptors recovers following
LVAD support of the failing human heart, the ratio of beta-1/beta-2 receptors remains at
failing (60/40) rather than non-failing (80/20) levels. The larger percentage of beta-2
receptors after LVAD may contribute to delayed recovery of the inotropic response.
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849-3 Extracellular Matrix Remodeling During Left Ventricular 
Assist Device Support: Relation Between Collagen and 
Passive Pressure-Volume Relations
Stefan Klotz, Marc L. Dickstein, Jeffrey A. Morgan, Robert F. Foronjy, Angou Gu, Jeanine 
D`Armentio, Daniel Burkhoff, Columbia University, New York, NY
Introduction: Left ventricular assist device (LVAD) support of failing hearts induces
reverse remodeling, manifest as shifts towards lower volumes of the passive pressure-
volume relationship (PVR). This may be a consequence of regression of hypertrophy
and/or changes in myocardial properties due to extracellular matrix remodeling. However,
the relative contributions of these factors to reverse remodeling are unknown.
Methods: LV tissue samples were collected from idiopathic dilated cardiomyopathic
(DCM) hearts at the time of cardiac transplantation in patients requiring (n=16) or not
requiring (n=16) prior LVAD support and from 5 normal hearts not suitable for transplan-
tation. Total collagen (hydroxyproline), soluble collagen and insoluble collagen were
determined. Chamber capacitance and myocardial stiffness were calculated from ex-vivo
PVRs and measured LV wall volume.
Results: Compared to normals, total collagen and soluble collagen were increased in
DCM (3.1±1.5 vs 6.1±3.4 µg/mg, p=0.014; 1.4±0.3 vs 4.1±0.9 µg/mg, respectively,
p<0.001). LVAD support further increased total collagen (9.0±3.3 µg/mg, p=0.019 vs
DCM), which was due to an increase of insoluble collagen (2.0±3.0 vs 5.1±3.1 µg/mg,
p=0.008) with no change in soluble collagen (4.1±0.9 vs 3.9±1.0, p=NS). LV mass was
decreased by LVAD support (296±73 vs 234±60 g, p=0.014), the PVR shifted towards
lower volumes with a chamber capacitance (volume at a pressure of 30 mmHg) decreas-
ing from 266±126 ml to 192±87 ml (p=0.024). However, myocardial stiffness constant
was not affected (9.9±0.7 vs 10.6±0.9, p=NS).
Discussion: LVAD-support of the failing human heart leads to increased total collagen
and cross-linking of collagen, suggestive of increased tensile strength of the extracellular
matrix. Despite these changes, however, global myocardial stiffness constant was unaf-
fected. These data lead to the provocative hypothesis that the profound changes induced
by LVADs indicative of reverse structural remodeling are mainly due to regression of myo-
cyte hypertrophy, with relatively little impact of the changes in collagen matrix on passive
myocardial properties.
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849-4 Soluble Tumor Necrosis Factor Receptor (Etanercept) 
Treatment Enhances Left Ventricular Dysfunction in an 
Experimental Model of Chronic Chagas Disease 
Cardiomyopathy
Angelina M. Bilate, Vera C. Salemi, Felix J. Ramires, Daniel Gregio, Jorge Kalil, Edecio 
Cunha-Neto, Heart Institute- University of São Paulo Medical School, São Paulo, Brazil
Background: chronic Chagas’ disease cardiomyopathy (CCC), caused by the protozoan
Trypanosoma cruzi, affects ca. 3 million patients in Latin America. The lack of proven effi-
cacious therapy is associated with worse prognosis of CCC. Chagas’disease is associ-
ated to increased production of proinflammatory cytokines such as TNF-alpha. The aim
of this work was to evaluate Etanercept, a TNF-blocking agent, as a potential therapeutic
approach in the control of CCC development. For that matter, we used as a model the
